Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy

Post-diagnosis Soy Food Intake and Breast Cancer Survival: A Meta-analysis of Cohort Studies

“…After reading full-texts, we excluded reviews (n =47), experimental studies (n =88) and not about survival (n=41). Finally, five cohort studies (six citations (Guha et al, 2009;Shu et al, 2009;Kang et al, 2010;Caan et al, 2011;Nechuta et al, 2012;Zhang et al, 2012)) (11206 patients) were included.…”

“…Three of them (Shu et al, 2009;Kang et al, 2010;Zhang et al, 2012) were form China and two (Guha et al, 2009;Caan et al, 2011) from USA. The total number ranges from 524 to 5042.…”

“…The total number ranges from 524 to 5042. Three of them (Guha et al, 2009;Kang et al, 2010;Zhang et al, 2012) were hospital-based and one (Shu et al, 2009) was community-based, and the last one (Caan et al, 2011) was unclear. The median follow-up ranged from 3.9 years to 7.3 years.…”

“…And another study conducted by Fink et al (Fink et al, 2007) reported that reduced hazard ratios [hazard ratio (95% confidence interval)] for all-cause mortality were observed among premenopausal and postmenopausal women for the highest quintile of intake prior to cancer diagnosis, compared with the lowest, for isoflavones [0.52 (0.33-0.82)]. Regarding to the associations between soy food intake after cancer diagnosis and survival (mortality or recurrence), the results were not the same based on available cohort studies (Guha et al, 2009;Shu et al, 2009;Kang et al, 2010;Caan et al, 2011;Nechuta et al, 2012;Zhang et al, 2012). One meta-analysis of four prospective cohort studies (Boyapati et al, 2005;Fink et al, 2007;Guha et al, 2009;Shu et al, 2009) showed that soy isoflavones intake was inversely associated with risk of breast cancer recurrence (Dong et al, 2011).…”

Caracterização de genótipos de soja-hortaliça por análise de componentes principais

“…al., 2002). Além disso, a presença de isoflavonas é associada com a geração de efeitos protetivos contra câncer de mama, próstata e cólon (POOL-ZOBEL et al, 2000;VASTAG, 2007;KANG et al, 2010).…”